|
1
|
Brown G: Targeting the retinoic acid
pathway to eradicate cancer stem cells. Int J Mol Sci. 24:23732023.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dick JE: Stem cell concepts renew cancer
research. Blood. 112:4793–4807. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hassan G and Seno M: Blood and cancer:
Cancer stem cells as origin of hematopoietic cells in solid tumor
microenvironments. Cells. 9:12932020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu S, Cong Y, Wang D, Sun Y, Deng L, Liu
Y, Martin-Trevino R, Shang L, McDermott SP, Landis MD, et al:
Breast cancer stem cells transition between epithelial and
mesenchymal states reflective of their normal counterparts. Stem
Cell Reports. 2:78–91. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li W, Ma H, Zhang J, Zhu L, Wang C and
Yang Y: Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem
cell markers in tumorigenesis and metastasis. Sci Rep. 7:138562017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kamalabadi Farahani M, Farjadmehr M,
Atashi A, Momeni A and Behzadifard M: Concise review: Breast cancer
stems cells and their role in metastases. Ann Med Surg (Lond).
86:5266–5275. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhong Y, Shen S, Zhou Y, Mao F, Guan J,
Lin Y, Xu Y and Sun Q: ALDH1 is a better clinical indicator for
relapse of invasive ductal breast cancer than the
CD44+/CD24-phenotype. Med Oncol. 31:8642014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Croker AK, Goodale D, Chu J, Postenka C,
Hedley BD, Hess DA and Allan AL: High aldehyde dehydrogenase and
expression of cancer stem cell markers selects for breast cancer
cells with enhanced malignant and metastatic ability. J Cell Mol
Med. 13:2236–2252. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Brugnoli F, Grassilli S, Al-Qassab Y,
Capitani S and Bertagnolo V: CD133 in breast cancer cells: More
than a stem cell marker. J Oncol. 2019:75126322019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xanthis V, Mantso T, Dimtsi A, Pappa A and
Fadouloglou VE: Human aldehyde dehydrogenases: A superfamily of
similar yet different proteins highly related to cancer. Cancers
(Basel). 15:44192023. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen Y, Thompson DC, Koppaka V, Jester JV
and Vasiliou V: Ocular aldehyde dehydrogenases: Protection against
ultraviolet damage and maintenance of transparency for vision. Prog
Retin Eye Res. 33:28–39. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shortall K, Djeghader A, Magner E and
Soulimane T: Insights into aldehyde dehydrogenase enzymes: A
structural perspective. Front Mol Biosci. 8:6595502021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sládek NE: Human aldehyde dehydrogenases:
Potential pathological, pharmacological, and toxicological impact.
J Biochem Mol Toxicol. 17:7–23. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
O'Brien PJ, Siraki AG and Shangari N:
Aldehyde sources, metabolism, molecular toxicity mechanisms, and
possible effects on human health. Crit Rev Toxicol. 35:609–662.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Marchitti SA, Brocker C, Stagos D and
Vasiliou V: Non-P450 aldehyde oxidizing enzymes: The aldehyde
dehydrogenase superfamily. Expert Opin Drug Metab Toxicol.
4:697–720. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ayala A, Muñoz MF and Argüelles S: Lipid
peroxidation: Production, metabolism, and signaling mechanisms of
malondialdehyde and 4-hydroxy-2-nonenal. Oxid Med Cell Longev.
2014:3604382014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sinharoy P, McAllister SL, Vasu M and
Gross ER: Environmental aldehyde sources and the health
implications of exposure. Adv Exp Med Biol. 1193:35–52. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zanoni M, Bravaccini S, Fabbri F and
Arienti C: Emerging roles of aldehyde dehydrogenase isoforms in
anti-cancer therapy resistance. Front Med (Lausanne). 9:7957622022.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jackson B, Brocker C, Thompson DC, Black
W, Vasiliou K, Nebert DW and Vasiliou V: Update on the aldehyde
dehydrogenase gene (ALDH) superfamily. Hum Genomics. 5:283–303.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Morgan CA, Parajuli B, Buchman CD, Dria K
and Hurley TD: N,N-diethylaminobenzaldehyde (DEAB) as a substrate
and mechanism-based inhibitor for human ALDH isoenzymes. Chem Biol
Interact. 234:18–28. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gomez-Salazar MA, Wang Y, Thottappillil N,
Hardy RW, Alexandre M, Höller F, Martin N, Gonzalez-Galofre ZN,
Stefancova D, Medici D, et al: Aldehyde dehydrogenase, a marker of
normal and malignant stem cells, typifies mesenchymal progenitors
in perivascular niches. Stem Cells Transl Med. 12:474–484. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ambroziak W, Izaguirre G and Pietruszko R:
Metabolism of retinaldehyde and other aldehydes in soluble extracts
of human liver and kidney. J Biol Chem. 274:33366–33373. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bui TBC, Nosaki S, Kokawa M, Xu Y,
Kitamura Y, Tanokura M, Hachimura S and Miyakawa T: Evaluation of
spice and herb as phyto-derived selective modulators of human
retinaldehyde dehydrogenases using a simple in vitro method.
Biosci Rep. 41:BSR202104912021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vasiliou V, Pappa A and Estey T: Role of
human aldehyde dehydrogenases in endobiotic and xenobiotic
metabolism. Drug Metab Rev. 36:279–299. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Egea J, Fabregat I, Frapart YM, Ghezzi P,
Görlach A, Kietzmann T, Kubaichuk K, Knaus UG, Lopez MG,
Olaso-Gonzalez G, et al: European contribution to the study of ROS:
A summary of the findings and prospects for the future from the
COST action BM1203 (EU-ROS). Redox Biol. 13:94–162. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dinavahi SS, Bazewicz CG, Gowda R and
Robertson GP: Aldehyde dehydrogenase inhibitors for cancer
therapeutics. Trends Pharmacol Sci. 40:774–789. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xia J, Li S, Liu S and Zhang L: Aldehyde
dehydrogenase in solid tumors and other diseases: Potential
biomarkers and therapeutic targets. MedComm (2020). 4:e1952023.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lavudi K, Nuguri SM, Pandey P, Kokkanti RR
and Wang QE: ALDH and cancer stem cells: Pathways, challenges, and
future directions in targeted therapy. Life Sci. 356:1230332024.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Al-Shamma SA, Zaher DM, Hersi F, Abu Jayab
NN and Omar HA: Targeting aldehyde dehydrogenase enzymes in
combination with chemotherapy and immunotherapy: An approach to
tackle resistance in cancer cells. Life Sci. 320:1215412023.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Stagos D, Chen Y, Cantore M, Jester JV and
Vasiliou V: Corneal aldehyde dehydrogenases: multiple functions and
novel nuclear localization. Brain Res Bull. 81:211–218. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhou L, Sheng D, Wang D, Ma W, Deng Q,
Deng L and Liu S: Identification of cancer-type specific expression
patterns for active aldehyde dehydrogenase (ALDH) isoforms in
ALDEFLUOR assay. Cell Biol Toxicol. 35:161–177. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Maggio V, Cánovas V, Félix AJ, Gómez V, de
Torres I, Semidey ME, Morote J, Noé V, Ciudad CJ and Paciucci R: A
novel DNA-binding motif in prostate tumor overexpressed-1 (PTOV1)
required for the expression of ALDH1A1 and CCNG2 in cancer cells.
Cancer Lett. 452:158–167. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lei F, Zhang L, Li X, Lin X, Wu S, Li F
and Liu J: Overexpression of prostate tumor overexpressed 1
correlates with tumor progression and predicts poor prognosis in
breast cancer. BMC Cancer. 14:4572014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Qing L, Li Q and Dong Z: MUC1: An emerging
target in cancer treatment and diagnosis. Bull Cancer.
109:1202–1216. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chen W, Zhang Z, Zhang S, Zhu P, Ko JK and
Yung KK: MUC1: Structure, function, and clinic application in
epithelial cancers. Int J Mol Sci. 22:65672021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ren J, Agata N, Chen D, Li Y, Yu WH, Huang
L, Raina D, Chen W, Kharbanda S and Kufe D: Human MUC1
carcinoma-associated protein confers resistance to genotoxic
anticancer agents. Cancer Cell. 5:163–175. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Alam M, Ahmad R, Rajabi H, Kharbanda A and
Kufe D: MUC1-C oncoprotein activates ERK-C/EBPβ signaling and
induction of aldehyde dehydrogenase 1A1 in breast cancer cells. J
Biol Chem. 288:30892–30903. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Alam M, Rajabi H, Ahmad R, Jin C and Kufe
D: Targeting the MUC1-C oncoprotein inhibits self-renewal capacity
of breast cancer cells. Oncotarget. 5:2622–2634. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jang GB, Hong IS, Kim RJ, Lee SY, Park SJ,
Lee ES, Park JH, Yun CH, Chung JU, Lee KJ, et al: Wnt/β-Catenin
Small-molecule inhibitor CWP232228 preferentially inhibits the
growth of breast cancer Stem-like cells. Cancer Res. 75:1691–1702.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
King TD, Suto MJ and Li Y: The
Wnt/β-catenin signaling pathway: A potential therapeutic target in
the treatment of triple negative breast cancer. J Cell Biochem.
113:13–18. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Cojoc M, Peitzsch C, Kurth I, Trautmann F,
Kunz-Schughart LA, Telegeev GD, Stakhovsky EA, Walker JR, Simin K,
Lyle S, et al: Aldehyde dehydrogenase is regulated by β-Catenin/TCF
and promotes radioresistance in prostate cancer progenitor cells.
Cancer Res. 75:1482–1494. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hoshino Y, Nishida J, Katsuno Y, Koinuma
D, Aoki T, Kokudo N, Miyazono K and Ehata S: Smad4 decreases the
population of pancreatic Cancer-initiating cells through
transcriptional repression of ALDH1A1. Am J Pathol. 185:1457–1470.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Varisli L and Vlahopoulos S:
Epithelial-Mesenchymal transition in acute leukemias. Int J Mol
Sci. 25:21732024. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kuburich NA, Sabapathy T, Demestichas BR,
Maddela JJ, den Hollander P and Mani SA: Proactive and reactive
roles of TGF-β in cancer. Semin Cancer Biol. 95:120–139. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Baba AB, Rah B, Bhat GR, Mushtaq I,
Parveen S, Hassan R, Hameed Zargar M and Afroze D: Transforming
growth Factor-Beta (TGF-β) signaling in Cancer-A betrayal within.
Front Pharmacol. 13:7912722022. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Varisli L, Tolan V, Cen JH, Vlahopoulos S
and Cen O: Dissecting the effects of androgen deprivation therapy
on cadherin switching in advanced prostate cancer: A molecular
perspective. Oncol Res. 30:137–155. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yu Q, Biswas S, Ma G, Zhao P, Li B and Li
J: Canonical NF-κB signaling maintains corneal epithelial integrity
and prevents corneal aging via retinoic acid. Elife. 10:e673152021.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Pavitra E, Kancharla J, Gupta VK, Prasad
K, Sung JY, Kim J, Tej MB, Choi R, Lee JH, Han YK, et al: The role
of NF-κB in breast cancer initiation, growth, metastasis, and
resistance to chemotherapy. Biomed Pharmacother. 163:1148222023.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Vlahopoulos SA, Cen O, Hengen N, Agan J,
Moschovi M, Critselis E, Adamaki M, Bacopoulou F, Copland JA,
Boldogh I, et al: Dynamic aberrant NF-κB spurs tumorigenesis: A new
model encompassing the microenvironment. Cytokine Growth Factor
Rev. 26:389–403. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Lambrou GI, Hatziagapiou K and Vlahopoulos
S: Inflammation and tissue homeostasis: The NF-κB system in
physiology and malignant progression. Mol Biol Rep. 47:4047–4063.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Vlahopoulos SA: Divergent processing of
cell stress signals as the basis of cancer progression: Licensing
NFκB on chromatin. Int J Mol Sci. 25:86212024. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhao D, Mo Y, Li MT, Zou SW, Cheng ZL, Sun
YP, Xiong Y, Guan KL and Lei QY: NOTCH-induced aldehyde
dehydrogenase 1A1 deacetylation promotes breast cancer stem cells.
J Clin Invest. 124:5453–5465. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wang J, Nikhil K, Viccaro K, Chang L,
White J and Shah K: Phosphorylation-dependent regulation of ALDH1A1
by Aurora kinase A: Insights on their synergistic relationship in
pancreatic cancer. BMC Biol. 15:102017. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ross AC and Moran NE: Our current dietary
reference intakes for vitamin A-Now 20 years old. Curr Dev Nutr.
4:nzaa0962020. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Surman SL, Penkert RR, Sealy RE, Jones BG,
Marion TN, Vogel P and Hurwitz JL: Consequences of vitamin a
deficiency: Immunoglobulin dysregulation, squamous cell metaplasia,
infectious disease, and death. Int J Mol Sci. 21:55702020.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Kedishvili NY: Enzymology of retinoic acid
biosynthesis and degradation. J Lipid Res. 54:1744–1760. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Belyaeva OV, Adams MK, Popov KM and
Kedishvili NY: Generation of retinaldehyde for retinoic acid
biosynthesis. Biomolecules. 10:52019. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Giguère V and Evans RM: Chronicle of a
discovery: The retinoic acid receptor. J Mol Endocrinol. 69:T1–T11.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Bastien J and Rochette-Egly C: Nuclear
retinoid receptors and the transcription of retinoid-target genes.
Gene. 328:1–16. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Jin Y, Teh SS, Lau HLN, Xiao J and Mah SH:
Retinoids as anti-cancer agents and their mechanisms of action. Am
J Cancer Res. 12:938–960. 2022.PubMed/NCBI
|
|
61
|
di Masi A, Leboffe L, De Marinis E, Pagano
F, Cicconi L, Rochette-Egly C, Lo-Coco F, Ascenzi P and Nervi C:
Retinoic acid receptors: From molecular mechanisms to cancer
therapy. Mol Aspects Med. 41:1–115. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Rastinejad F: Retinoic acid receptor
structures: The journey from single domains to full-length complex.
J Mol Endocrinol. 69:T25–T36. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Wolf G: Retinoic acid as cause of cell
proliferation or cell growth inhibition depending on activation of
one of two different nuclear receptors. Nutr Rev. 66:55–59. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Ross-Innes CS, Stark R, Holmes KA, Schmidt
D, Spyrou C, Russell R, Massie CE, Vowler SL, Eldridge M and
Carroll JS: Cooperative interaction between retinoic acid
receptor-alpha and estrogen receptor in breast cancer. Genes Dev.
24:171–182. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Piskunov A, Al Tanoury Z and Rochette-Egly
C: Nuclear and extra-nuclear effects of retinoid acid receptors:
How they are interconnected. Subcell Biochem. 70:103–127. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Sharma S, Sharma P, Bailey T, Bhattarai S,
Subedi U, Miller C, Ara H, Kidambi S, Sun H, Panchatcharam M and
Miriyala S: Electrophilic aldehyde 4-Hydroxy-2-nonenal mediated
signaling and mitochondrial dysfunction. Biomolecules. 12:15552022.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Hu W, Feng Z, Eveleigh J, Iyer G, Pan J,
Amin S, Chung FL and Tang MS: The major lipid peroxidation product,
trans-4-hydroxy-2-nonenal, preferentially forms DNA adducts at
codon 249 of human p53 gene, a unique mutational hotspot in
hepatocellular carcinoma. Carcinogenesis. 23:1781–1789. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Suman S, Kumar S, N'Gouemo P and Datta K:
Increased DNA double-strand break was associated with
downregulation of repair and upregulation of apoptotic factors in
rat hippocampus after alcohol exposure. Alcohol. 54:45–50. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Zhang Y, Wang H, Wu K and Liu Z:
Expression of 4-hydroxynonenal in esophageal squamous cell
carcinoma. Oncol Lett. 14:35–40. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Yang Y, Huycke MM, Herman TS and Wang X:
Glutathione S-transferase alpha 4 induction by activator protein 1
in colorectal cancer. Oncogene. 35:5795–5806. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Gęgotek A, Nikliński J, Žarković N,
Žarković K, Waeg G, Łuczaj W, Charkiewicz R and Skrzydlewska E:
Lipid mediators involved in the oxidative stress and antioxidant
defence of human lung cancer cells. Redox Biol. 9:210–219. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Fritz KS and Petersen DR: An overview of
the chemistry and biology of reactive aldehydes. Free Radic Biol
Med. 59:85–91. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Sener DE, Gönenç A, Akinci M and Torun M:
Lipid peroxidation and total antioxidant status in patients with
breast cancer. Cell Biochem Funct. 25:377–382. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Hassan W, Noreen H, Rehman S, Kamal MA and
da Rocha JBT: Association of oxidative stress with neurological
disorders. Curr Neuropharmacol. 20:1046–1072. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Menon B, Ramalingam K and Kumar R:
Evaluating the role of oxidative stress in acute ischemic stroke. J
Neurosci Rural Pract. 11:156–159. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Jové M, Mota-Martorell N, Pradas I,
Martín-Gari M, Ayala V and Pamplona R: The advanced lipoxidation
End-product Malondialdehyde-lysine in aging and longevity.
Antioxidants (Basel). 9:11322020. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Naudí A, Jové M, Ayala V, Cabré R,
Portero-Otín M and Pamplona R: Non-enzymatic modification of
aminophospholipids by carbonyl-amine reactions. Int J Mol Sci.
14:3285–3313. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Plastaras JP, Dedon PC and Marnett LJ:
Effects of DNA structure on oxopropenylation by the endogenous
mutagens malondialdehyde and base propenal. Biochemistry.
41:5033–5042. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Wauchope OR, Mitchener MM, Beavers WN,
Galligan JJ, Camarillo JM, Sanders WD, Kingsley PJ, Shim HN,
Blackwell T, Luong T, et al: Oxidative stress increases M1dG, a
major peroxidation-derived DNA adduct, in mitochondrial DNA.
Nucleic Acids Res. 46:3458–3467. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Feng Z, Hu W, Marnett LJ and Tang M:
Malondialdehyde, a major endogenous lipid peroxidation product,
sensitizes human cells to UV- and BPDE-induced killing and
mutagenesis through inhibition of nucleotide excision repair. Mutat
Res. 601:125–136. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Ramana KV, Srivastava S and Singhal SS:
Lipid peroxidation products in human health and disease 2016. Oxid
Med Cell Longev. 2017:21632852017. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Dancik GM, Varisli L and Vlahopoulos SA:
The molecular context of oxidant stress response in cancer
establishes ALDH1A1 as a critical target: What this means for acute
myeloid leukemia. Int J Mol Sci. 24:93722023. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Yue H, Hu Z, Hu R, Guo Z, Zheng Y, Wang Y
and Zhou Y: ALDH1A1 in cancers: Bidirectional function, drug
resistance, and regulatory mechanism. Front Oncol. 12:9187782022.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Tomita H, Tanaka K, Tanaka T and Hara A:
Aldehyde dehydrogenase 1A1 in stem cells and cancer. Oncotarget.
7:11018–11032. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Stromskaya TP, Rybalkina EY, Zabotina TN,
Shishkin AA and Stavrovskaya AA: Influence of RARalpha gene on MDR1
expression and P-glycoprotein function in human leukemic cells.
Cancer Cell Int. 5:152005. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Poturnajova M, Kozovska Z and Matuskova M:
Aldehyde dehydrogenase 1A1 and 1A3 isoforms-mechanism of activation
and regulation in cancer. Cell Signal. 87:1101202021. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Wei Y, Li Y, Chen Y, Liu P, Huang S, Zhang
Y, Sun Y, Wu Z, Hu M, Wu Q, et al: ALDH1: A potential therapeutic
target for cancer stem cells in solid tumors. Front Oncol.
12:10262782022. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Yang L, Shi P, Zhao G, Xu J, Peng W, Zhang
J, Zhang G, Wang X, Dong Z, Chen F and Cui H: Targeting cancer stem
cell pathways for cancer therapy. Signal Transduct Target Ther.
5:82020. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Ciccone V, Morbidelli L, Ziche M and
Donnini S: How to conjugate the stemness marker ALDH1A1 with tumor
angiogenesis, progression, and drug resistance. Cancer Drug Resist.
3:26–37. 2020.PubMed/NCBI
|
|
90
|
Zhou L, Jiang Y, Yan T, Di G, Shen Z, Shao
Z and Lu J: The prognostic role of cancer stem cells in breast
cancer: A meta-analysis of published literatures. Breast Cancer Res
Treat. 122:795–801. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Kim YS, Jung MJ, Ryu DW and Lee CH:
Clinicopathologic characteristics of breast cancer stem cells
identified on the basis of aldehyde dehydrogenase 1 expression. J
Breast Cancer. 17:121–128. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Miyoshi Y, Shien T, Ogiya A, Ishida N,
Yamazaki K, Horii R, Horimoto Y, Masuda N, Yasojima H, Inao T, et
al: Differences in expression of the cancer stem cell marker
aldehyde dehydrogenase 1 among estrogen receptor-positive/human
epidermal growth factor receptor type 2-negative breast cancer
cases with early, late, and no recurrence. Breast Cancer Res.
18:732016. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Li H, Ma F, Wang H, Lin C, Fan Y, Zhang X,
Qian H and Xu B: Stem cell marker aldehyde dehydrogenase 1
(ALDH1)-expressing cells are enriched in triple-negative breast
cancer. Int J Biol Markers. 28:e357–e364. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Ma F, Li H, Li Y, Ding X, Wang H, Fan Y,
Lin C, Qian H and Xu B: Aldehyde dehydrogenase 1 (ALDH1) expression
is an independent prognostic factor in triple negative breast
cancer (TNBC). Medicine (Baltimore). 96:e65612017. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Liu Y, Lv DL, Duan JJ, Xu SL, Zhang JF,
Yang XJ, Zhang X, Cui YH, Bian XW and Yu SC: ALDH1A1 expression
correlates with clinicopathologic features and poor prognosis of
breast cancer patients: A systematic review and meta-analysis. BMC
Cancer. 14:4442014. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Morimoto K, Kim SJ, Tanei T, Shimazu K,
Tanji Y, Taguchi T, Tamaki Y, Terada N and Noguchi S: Stem cell
marker aldehyde dehydrogenase 1-positive breast cancers are
characterized by negative estrogen receptor, positive human
epidermal growth factor receptor type 2, and high Ki67 expression.
Cancer Sci. 100:1062–1068. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Althobiti M, El Ansari R, Aleskandarany M,
Joseph C, Toss MS, Green AR and Rakha EA: The prognostic
significance of ALDH1A1 expression in early invasive breast cancer.
Histopathology. 77:437–448. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Kang EJ, Jung H, Woo OH, Park KH, Woo SU,
Yang DS, Kim AR, Lee JB, Kim YH, Kim JS and Seo JH: Association of
aldehyde dehydrogenase 1 expression and biologically aggressive
features in breast cancer. Neoplasma. 61:352–362. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Yao J, Jin Q, Wang XD, Zhu HJ and Ni QC:
Aldehyde dehydrogenase 1 expression is correlated with poor
prognosis in breast cancer. Medicine (Baltimore). 96:e71712017.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Ohi Y, Umekita Y, Yoshioka T, Souda M, Rai
Y, Sagara Y, Sagara Y, Sagara Y and Tanimoto A: Aldehyde
dehydrogenase 1 expression predicts poor prognosis in
triple-negative breast cancer. Histopathology. 59:776–780. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Nogami T, Shien T, Tanaka T, Nishiyama K,
Mizoo T, Iwamto T, Ikeda H, Taira N, Doihara H and Miyoshi S:
Expression of ALDH1 in axillary lymph node metastases is a
prognostic factor of poor clinical outcome in breast cancer
patients with 1–3 lymph node metastases. Breast Cancer. 21:58–65.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Dong Y, Bi LR, Xu N, Yang HM, Zhang HT,
Ding Y, Shi AP and Fan ZM: The expression of aldehyde dehydrogenase
1 in invasive primary breast tumors and axillary lymph node
metastases is associated with poor clinical prognosis. Pathol Res
Pract. 209:555–561. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Kong Y, Lyu N, Wu J, Tang H and Xie X,
Yang L, Li X, Wei W and Xie X: Breast cancer stem cell markers CD44
and ALDH1A1 in serum: Distribution and prognostic value in patients
with primary breast cancer. J Cancer. 9:3728–3735. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Resetkova E, Reis-Filho JS, Jain RK, Mehta
R, Thorat MA, Nakshatri H and Badve S: Prognostic impact of ALDH1
in breast cancer: A story of stem cells and tumor microenvironment.
Breast Cancer Res Treat. 123:97–108. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Honeth G, Lombardi S, Ginestier C, Hur M,
Marlow R, Buchupalli B, Shinomiya I, Gazinska P, Bombelli S,
Ramalingam V, et al: Aldehyde dehydrogenase and estrogen receptor
define a hierarchy of cellular differentiation in the normal human
mammary epithelium. Breast Cancer Res. 16:R522014. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Sarmiento-Castro A, Caamaño-Gutiérrez E,
Sims AH, Hull NJ, James MI, Santiago-Gómez A, Eyre R, Clark C,
Brown ME, Brooks MD, et al: Increased expression of Interleukin-1
receptor characterizes Anti-estrogen-Resistant ALDH+ breast cancer
stem cells. Stem Cell Reports. 15:307–316. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Wang Q, Jiang J, Ying G, Xie XQ, Zhang X,
Xu W, Zhang X, Song E, Bu H, Ping YF, et al: Tamoxifen enhances
stemness and promotes metastasis of ERα36+ breast cancer by
upregulating ALDH1A1 in cancer cells. Cell Res. 28:336–358. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Varisli L, Dancik GM, Tolan V and
Vlahopoulos S: Critical roles of SRC-3 in the development and
progression of breast cancer, rendering it a prospective clinical
target. Cancers (Basel). 15:52422023. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Brown K, Chen Y, Underhill TM, Mymryk JS
and Torchia J: The coactivator p/CIP/SRC-3 facilitates retinoic
acid receptor signaling via recruitment of GCN5. J Biol Chem.
278:39402–39412. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Ferry C, Gaouar S, Fischer B, Boeglin M,
Paul N, Samarut E, Piskunov A, Pankotai-Bodo G, Brino L and
Rochette-Egly C: Cullin 3 mediates SRC-3 ubiquitination and
degradation to control the retinoic acid response. Proc Natl Acad
Sci USA. 108:20603–20608. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Giannì M, Parrella E, Raska I Jr, Gaillard
E, Nigro EA, Gaudon C, Garattini E and Rochette-Egly C:
P38MAPK-dependent phosphorylation and degradation of SRC-3/AIB1 and
RARalpha-mediated transcription. EMBO J. 25:739–751. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Rohira AD, Yan F, Wang L, Wang J, Zhou S,
Lu A, Yu Y, Xu J, Lonard DM and O'Malley BW: Targeting SRC
coactivators blocks the Tumor-initiating capacity of cancer
stem-like cells. Cancer Res. 77:4293–4304. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Fitzgerald P, Teng M, Chandraratna RA,
Heyman RA and Allegretto EA: Retinoic acid receptor alpha
expression correlates with retinoid-induced growth inhibition of
human breast cancer cells regardless of estrogen receptor status.
Cancer Res. 57:2642–2650. 1997.PubMed/NCBI
|
|
114
|
Garattini E, Bolis M, Garattini SK,
Fratelli M, Centritto F, Paroni G, Gianni' M, Zanetti A, Pagani A,
Fisher JN, et al: Retinoids and breast cancer: From basic studies
to the clinic and back again. Cancer Treat Rev. 40:739–749. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Liu Y, Lee MO, Wang HG, Li Y, Hashimoto Y,
Klaus M, Reed JC and Zhang X: Retinoic acid receptor beta mediates
the growth-inhibitory effect of retinoic acid by promoting
apoptosis in human breast cancer cells. Mol Cell Biol.
16:1138–1149. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Centritto F, Paroni G, Bolis M, Garattini
SK, Kurosaki M, Barzago MM, Zanetti A, Fisher JN, Scott MF, Pattini
L, et al: Cellular and molecular determinants of all-trans retinoic
acid sensitivity in breast cancer: Luminal phenotype and RARα
expression. EMBO Mol Med. 7:950–972. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Roman SD, Ormandy CJ, Manning DL, Blamey
RW, Nicholson RI, Sutherland RL and Clarke CL: Estradiol induction
of retinoic acid receptors in human breast cancer cells. Cancer
Res. 53:5940–5945. 1993.PubMed/NCBI
|
|
118
|
Hua S, Kittler R and White KP: Genomic
antagonism between retinoic acid and estrogen signaling in breast
cancer. Cell. 137:2009. View Article : Google Scholar
|
|
119
|
Ombra MN, Di Santi A, Abbondanza C,
Migliaccio A, Avvedimento EV and Perillo B: Retinoic acid impairs
estrogen signaling in breast cancer cells by interfering with
activation of LSD1 via PKA. Biochim Biophys Acta. 1829:480–486.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Charafe-Jauffret E, Ginestier C, Iovino F,
Tarpin C, Diebel M, Esterni B, Houvenaeghel G, Extra JM, Bertucci
F, Jacquemier J, et al: Aldehyde dehydrogenase 1-positive cancer
stem cells mediate metastasis and poor clinical outcome in
inflammatory breast cancer. Clin Cancer Res. 16:45–55. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Croker AK, Rodriguez-Torres M, Xia Y,
Pardhan S, Leong HS, Lewis JD and Allan AL: Differential functional
roles of ALDH1A1 and ALDH1A3 in mediating metastatic behavior and
therapy resistance of human breast cancer cells. Int J Mol Sci.
18:20392017. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Pan H, Wu N, Huang Y, Li Q, Liu C, Liang
M, Zhou W, Liu X and Wang S: Aldehyde dehydrogenase 1 expression
correlates with the invasion of breast cancer. Diagn Pathol.
10:662015. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Sakakibara M, Fujimori T, Miyoshi T,
Nagashima T, Fujimoto H, Suzuki HT, Ohki Y, Fushimi K, Yokomizo J,
Nakatani Y and Miyazaki M: Aldehyde dehydrogenase 1-positive cells
in axillary lymph node metastases after chemotherapy as a
prognostic factor in patients with lymph node-positive breast
cancer. Cancer. 118:3899–3910. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Liang L and Kaufmann AM: The significance
of cancer stem cells and Epithelial-Mesenchymal transition in
metastasis and Anti-cancer therapy. Int J Mol Sci. 24:25552023.
View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Papadaki MA, Stoupis G, Theodoropoulos PA,
Mavroudis D, Georgoulias V and Agelaki S: Circulating tumor cells
with stemness and Epithelial-to-Mesenchymal transition features are
chemoresistant and predictive of poor outcome in metastatic breast
cancer. Mol Cancer Ther. 18:437–447. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Hashemi M, Arani HZ, Orouei S, Fallah S,
Ghorbani A, Khaledabadi M, Kakavand A, Tavakolpournegari A, Saebfar
H, Heidari H, et al: EMT mechanism in breast cancer metastasis and
drug resistance: Revisiting molecular interactions and biological
functions. Biomed Pharmacother. 155:1137742022. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Francou A and Anderson KV: The
Epithelial-to-Mesenchymal transition (EMT) in development and
cancer. Annu Rev Cancer Biol. 4:197–220. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Varisli L and Tolan V: Increased ROS
alters E-/N-cadherin levels and promotes migration in prostate
cancer cells. Bratisl Lek Listy. 123:752–757. 2022.PubMed/NCBI
|
|
129
|
Raimondi C, Gradilone A, Naso G, Vincenzi
B, Petracca A, Nicolazzo C, Palazzo A, Saltarelli R, Spremberg F,
Cortesi E and Gazzaniga P: Epithelial-mesenchymal transition and
stemness features in circulating tumor cells from breast cancer
patients. Breast Cancer Res Treat. 130:449–455. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Kallergi G, Papadaki MA, Politaki E,
Mavroudis D, Georgoulias V and Agelaki S: Epithelial to mesenchymal
transition markers expressed in circulating tumour cells of early
and metastatic breast cancer patients. Breast Cancer Res.
13:R592011. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Papadaki MA, Kallergi G, Zafeiriou Z,
Manouras L, Theodoropoulos PA, Mavroudis D, Georgoulias V and
Agelaki S: Co-expression of putative stemness and
epithelial-to-mesenchymal transition markers on single circulating
tumour cells from patients with early and metastatic breast cancer.
BMC Cancer. 14:6512014. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Vesuna F, Lisok A, Kimble B and Raman V:
Twist modulates breast cancer stem cells by transcriptional
regulation of CD24 expression. Neoplasia. 11:1318–1328. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Ito M, Shien T, Omori M, Mizoo T, Iwamoto
T, Nogami T, Motoki T, Taira N, Doihara H and Miyoshi S: Evaluation
of aldehyde dehydrogenase 1 and transcription factors in both
primary breast cancer and axillary lymph node metastases as a
prognostic factor. Breast Cancer. 23:437–444. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Ciccone V, Terzuoli E, Donnini S,
Giachetti A, Morbidelli L and Ziche M: Stemness marker ALDH1A1
promotes tumor angiogenesis via retinoic acid/HIF-1α/VEGF
signalling in MCF-7 breast cancer cells. J Exp Clin Cancer Res.
37:3112018. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
DA Cruz Paula A, Marques O, Sampaio R,
Rosa A, Garcia J, Rêma A, DE Fátima Faria M, Silva P, Vizcaíno R
and Lopes C: Characterization of CD44+ALDH1+Ki-67-Cells in
Non-malignant and neoplastic lesions of the breast. Anticancer Res.
36:4629–4638. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Walter D, Lier A, Geiselhart A, Thalheimer
FB, Huntscha S, Sobotta MC, Moehrle B, Brocks D, Bayindir I,
Kaschutnig P, et al: Exit from dormancy provokes DNA-damage-induced
attrition in haematopoietic stem cells. Nature. 520:549–552. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Lynch J, Troadec E, Fung TK, Gladysz K,
Virely C, Lau PNI, Cheung N, Zeisig B, Wong JWH, Lopes M, et al:
Hematopoietic stem cell quiescence and DNA replication dynamics
maintained by the resilient β-catenin/Hoxa9/Prmt1 axis. Blood.
143:1586–1598. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Xu J, Fei P, Simon DW, Morowitz MJ, Mehta
PA and Du W: Crosstalk between DNA damage repair and metabolic
regulation in hematopoietic stem cells. Cells. 13:7332024.
View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Becker F, Ouzin M, Liedtke S, Raba K and
Kogler G: DNA damage response after treatment of cycling and
quiescent cord blood hematopoietic stem cells with distinct
genotoxic noxae. Stem Cells. 42:158–171. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Pallis M, Burrows F, Whittall A, Boddy N,
Seedhouse C and Russell N: Efficacy of RNA polymerase II inhibitors
in targeting dormant leukaemia cells. BMC Pharmacol Toxicol.
14:322013. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Min HY and Lee HY: Cellular dormancy in
cancer: Mechanisms and potential targeting strategies. Cancer Res
Treat. 55:720–736. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Goldman MJ, Craft B, Hastie M, Repečka K,
McDade F, Kamath A, Banerjee A, Luo Y, Rogers D, Brooks AN, et al:
Visualizing and interpreting cancer genomics data via the Xena
platform. Nat Biotechnol. 38:675–678. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Vlahopoulos S, Pan L, Varisli L, Dancik
GM, Karantanos T and Boldogh I: OGG1 as an epigenetic reader
affects NFκB: What this means for cancer. Cancers (Basel).
16:1482023. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Bidan N, Bailleul-Dubois J, Duval J,
Winter M, Denoulet M, Hannebicque K, El-Sayed IY, Ginestier C,
Forissier V, Charafe-Jauffret E, et al: Transcriptomic analysis of
breast cancer stem cells and development of a pALDH1A1:mNeptune
reporter system for live tracking. Proteomics. 19:e18004542019.
View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Enikeev AD, Abramov PM, Elkin DS, Komelkov
AV, Beliaeva AA, Silantieva DM and Tchevkina EM: Opposite effects
of CRABP1 and CRABP2 homologs on proliferation of breast cancer
cells and their sensitivity to retinoic acid. Biochemistry (Mosc).
88:2107–2124. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Brown G: Deregulation of All-trans
retinoic acid signaling and development in cancer. Int J Mol Sci.
24:120892023. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Patel M, Lu L, Zander DS, Sreerama L, Coco
D and Moreb JS: ALDH1A1 and ALDH3A1 expression in lung cancers:
Correlation with histologic type and potential precursors. Lung
Cancer. 59:340–349. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Li Z, Xiang Y, Xiang L, Xiao Y, Li F and
Hao P: ALDH maintains the stemness of lung adenoma stem cells by
suppressing the Notch/CDK2/CCNE pathway. PLoS One. 9:e926692014.
View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Yassin Fel-Z: Aldehyde dehyderogenase
(ALDH1A1) delineating the normal and cancer stem cells in spectral
lung lesions: An immunohistochemical appraisal. Pathol Res Pract.
212:398–409. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Wei Y, Wu S, Xu W, Liang Y, Li Y, Zhao W
and Wu J: Depleted aldehyde dehydrogenase 1A1 (ALDH1A1) reverses
cisplatin resistance of human lung adenocarcinoma cell A549/DDP.
Thorac Cancer. 8:26–32. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Liu X, Wang L, Cui W, Yuan X, Lin L, Cao
Q, Wang N, Li Y, Guo W, Zhang X, et al: Targeting ALDH1A1 by
disulfiram/copper complex inhibits non-small cell lung cancer
recurrence driven by ALDH-positive cancer stem cells. Oncotarget.
7:58516–58530. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Gao F, Zhou B, Xu JC, Gao X, Li SX, Zhu
GC, Zhang XG and Yang C: The role of LGR5 and ALDH1A1 in non-small
cell lung cancer: Cancer progression and prognosis. Biochem Biophys
Res Commun. 462:91–98. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Alamgeer M, Ganju V, Szczepny A, Russell
PA, Prodanovic Z, Kumar B, Wainer Z, Brown T, Schneider-Kolsky M,
Conron M, et al: The prognostic significance of aldehyde
dehydrogenase 1A1 (ALDH1A1) and CD133 expression in early stage
non-small cell lung cancer. Thorax. 68:1095–1104. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Li D, Cao Y, Luo CW, Zhang LP and Zou YB:
The clinical significance and prognostic value of ALDH1 expression
in non-small cell lung cancer: A systematic review and
meta-analysis. Recent Pat Anticancer Drug Discov. 19:599–609. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Biswas AK, Han S, Tai Y, Ma W, Coker C,
Quinn SA, Shakri AR, Zhong TJ, Scholze H, Lagos GG, et al:
Targeting S100A9-ALDH1A1-Retinoic acid signaling to suppress brain
relapse in EGFR-mutant lung cancer. Cancer Discov. 12:1002–1021.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Okudela K, Woo T, Mitsui H, Suzuki T,
Tajiri M, Sakuma Y, Miyagi Y, Tateishi Y, Umeda S, Masuda M and
Ohashi K: Downregulation of ALDH1A1 expression in non-small cell
lung carcinomas-its clinicopathologic and biological significance.
Int J Clin Exp Pathol. 6:1–12. 2013.PubMed/NCBI
|
|
157
|
Yamashita N, So T, Miyata T, Yoshimatsu T,
Nakano R, Oyama T, Matsunaga W and Gotoh A: Triple-negative
expression (ALDH1A1-/CD133-/mutant p53-) cases in lung
adenocarcinoma had a good prognosis. Sci Rep. 12:14732022.
View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Pelos G, Riester M, Pal J, Myacheva K,
Moneke I, Rotondo JC, Lübbert M and Diederichs S: Fast
proliferating and slowly migrating non-small cell lung cancer cells
are vulnerable to decitabine and retinoic acid combinatorial
treatment. Int J Cancer. 154:1029–1042. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Zito G, Naselli F, Saieva L, Raimondo S,
Calabrese G, Guzzardo C, Forte S, Rolfo C, Parenti R and Alessandro
R: Retinoic Acid affects Lung adenocarcinoma growth by inducing
differentiation via GATA6 activation and EGFR and Wnt inhibition.
Sci Rep. 7:47702017. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Li D, Sun J, Liu W, Wang X, Bals R, Wu J,
Quan W, Yao Y, Zhang Y, Zhou H and Wu K: Rig-G is a growth
inhibitory factor of lung cancer cells that suppresses STAT3 and
NF-κB. Oncotarget. 7:66032–66050. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Rehó B, Fadel L, Brazda P, Benziane A,
Hegedüs É, Sen P, Gadella TWJ, Tóth K, Nagy L and Vámosi G:
Agonist-controlled competition of RAR and VDR nuclear receptors for
heterodimerization with RXR is manifested in their DNA binding. J
Biol Chem. 299:1028962023. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
López-Fandiño R, Molina E and
Lozano-Ojalvo D: Intestinal factors promoting the development of
RORγt+ cells and oral tolerance. Front Immunol. 14:12942922023.
View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Le Magnen C, Bubendorf L, Rentsch CA,
Mengus C, Gsponer J, Zellweger T, Rieken M, Thalmann GN, Cecchini
MG, Germann M, et al: Characterization and clinical relevance of
ALDHbright populations in prostate cancer. Clin Cancer Res.
19:5361–5371. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Gorodetska I, Offermann A, Püschel J,
Lukiyanchuk V, Gaete D, Kurzyukova A, Freytag V, Haider MT, Fjeldbo
CS, Di Gaetano S, et al: ALDH1A1 drives prostate cancer metastases
and radioresistance by interplay with AR- and RAR-dependent
transcription. Theranostics. 14:714–737. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Nastały P, Filipska M, Morrissey C, Eltze
E, Semjonow A, Brandt B, Pantel K and Bednarz-Knoll N:
ALDH1-positive intratumoral stromal cells indicate differentiated
epithelial-like phenotype and good prognosis in prostate cancer.
Transl Res. 203:49–56. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Liu Z, Ren G, Shangguan C, Guo L, Dong Z,
Li Y, Zhang W, Zhao L, Hou P, Zhang Y, et al: ATRA inhibits the
proliferation of DU145 prostate cancer cells through reducing the
methylation level of HOXB13 gene. PLoS One. 7:e409432012.
View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Landen CN Jr, Goodman B, Katre AA, Steg
AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB, Gershenson
DM, et al: Targeting aldehyde dehydrogenase cancer stem cells in
ovarian cancer. Mol Cancer Ther. 9:3186–3199. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Izycka N, Rucinski M, Andrzejewska M,
Szubert S, Nowak-Markwitz E and Sterzynska K: The prognostic value
of cancer stem cell markers (CSCs) Expression-ALDH1A1, CD133,
CD44-For survival and long-term follow-up of ovarian cancer
patients. Int J Mol Sci. 24:24002023. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Meng E, Mitra A, Tripathi K, Finan MA,
Scalici J, McClellan S, Madeira da Silva L, Reed E, Shevde LA,
Palle K and Rocconi RP: ALDH1A1 maintains ovarian cancer stem
cell-like properties by altered regulation of cell cycle checkpoint
and DNA repair network signaling. PLoS One. 9:e1071422014.
View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Kaipio K, Chen P, Roering P, Huhtinen K,
Mikkonen P, Östling P, Lehtinen L, Mansuri N, Korpela T, Potdar S,
et al: ALDH1A1-related stemness in high-grade serous ovarian cancer
is a negative prognostic indicator but potentially targetable by
EGFR/mTOR-PI3K/aurora kinase inhibitors. J Pathol. 250:159–169.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Januchowski R, Wojtowicz K, Sterzyſska K,
Sosiſska P, Andrzejewska M, Zawierucha P, Nowicki M and Zabel M:
Inhibition of ALDH1A1 activity decreases expression of drug
transporters and reduces chemotherapy resistance in ovarian cancer
cell lines. Int J Biochem Cell Biol. 78:248–259. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Nowacka M, Ginter-Matuszewska B,
Świerczewska M, Sterzyńska K, Nowicki M and Januchowski R: Effect
of ALDH1A1 gene knockout on drug resistance in paclitaxel and
topotecan resistant human ovarian cancer cell lines in 2D and 3D
model. Int J Mol Sci. 23:30362022. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Muralikrishnan V, Fang F, Given TC,
Podicheti R, Chtcherbinine M, Metcalfe TX, Sriramkumar S, O'Hagan
HM, Hurley TD and Nephew KP: A novel ALDH1A1 inhibitor blocks
platinum-induced senescence and stemness in ovarian cancer. Cancers
(Basel). 14:34372022. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Sharbatoghli M, Shamshiripour P, Fattahi
F, Kalantari E, Habibi Shams Z, Panahi M, Totonchi M, Asadi-Lari Z,
Madjd Z and Saeednejad Zanjani L: Co-expression of cancer stem cell
markers, SALL4/ALDH1A1, is associated with tumor aggressiveness and
poor survival in patients with serous ovarian carcinoma. J Ovarian
Res. 15:172022. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Dancik GM, Voutsas IF and Vlahopoulos S:
Lower RNA expression of ALDH1A1 distinguishes the favorable risk
group in acute myeloid leukemia. Mol Biol Rep. 49:3321–3331. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Gasparetto M, Pei S, Minhajuddin M, Khan
N, Pollyea DA, Myers JR, Ashton JM, Becker MW, Vasiliou V,
Humphries KR, et al: Targeted therapy for a subset of acute myeloid
leukemias that lack expression of aldehyde dehydrogenase 1A1.
Haematologica. 102:1054–1065. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Venton G, Pérez-Alea M, Baier C, Fournet
G, Quash G, Labiad Y, Martin G, Sanderson F, Poullin P, Suchon P,
et al: Aldehyde dehydrogenases inhibition eradicates leukemia stem
cells while sparing normal progenitors. Blood Cancer J. 6:e4692016.
View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Rebollido-Rios R, Venton G,
Sánchez-Redondo S, Iglesias I, Felip C, Fournet G, González E,
Romero Fernández W, Borroto Escuela DO, Di Stefano B,
Penarroche-Díaz R, et al: Dual disruption of aldehyde
dehydrogenases 1 and 3 promotes functional changes in the
glutathione redox system and enhances chemosensitivity in nonsmall
cell lung cancer. Oncogene. 39:2756–2771. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Law R: Advanced BioDesign releases
positive data from ODYSSEY AML study. Clinical Trials Arena. June
6–2024.
|
|
180
|
Venton G, Colle J, Tichadou A, Quessada J,
Baier C, Labiad Y, Perez M, De Lassus L, Loosveld M, Arnoux I, et
al: Reactive oxygen species and aldehyde dehydrogenase 1A as
prognosis and theragnostic biomarker in acute myeloid leukaemia
patients. J Cell Mol Med. 28:e700112024. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Yasgar A, Titus SA, Wang Y, Danchik C,
Yang SM, Vasiliou V, Jadhav A, Maloney DJ, Simeonov A and Martinez
NJ: A High-content assay enables the automated screening and
identification of small molecules with specific ALDH1A1-inhibitory
activity. PLoS One. 12:e01709372017. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Xu B, Wang S, Li R, Chen K, He L, Deng M,
Kannappan V, Zha J, Dong H and Wang W: Disulfiram/copper
selectively eradicates AML leukemia stem cells in vitro and in vivo
by simultaneous induction of ROS-JNK and inhibition of NF-κB and
Nrf2. Cell Death Dis. 8:e27972017. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Dancik GM, Voutsas IF and Vlahopoulos S:
Aldehyde dehydrogenase enzyme functions in acute leukemia stem
cells. Front Biosci (Schol Ed). 14:82022. View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Ghiaur G, Yegnasubramanian S, Perkins B,
Gucwa JL, Gerber JM and Jones RJ: Regulation of human hematopoietic
stem cell self-renewal by the microenvironment's control of
retinoic acid signaling. Proc Natl Acad Sci USA. 110:16121–16126.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Alonso S, Jones RJ and Ghiaur G: Retinoic
acid, CYP26, and drug resistance in the stem cell niche. Exp
Hematol. 54:17–25. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Bunaciu RP, MacDonald RJ, Gao F, Johnson
LM, Varner JD, Wang X, Nataraj S, Guzman ML and Yen A: Potential
for subsets of wt-NPM1 primary AML blasts to respond to retinoic
acid treatment. Oncotarget. 9:4134–4149. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
McGinn O, Riley D, Finlay-Schultz J, Paul
KV, Kabos P and Sartorius CA: Cytokeratins 5 and 17 maintain an
aggressive epithelial state in basal-like breast cancer. Mol Cancer
Res. 20:1443–1455. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Yang Y, Zhou W, Xia J, Gu Z, Wendlandt E,
Zhan X, Janz S, Tricot G and Zhan F: NEK2 mediates
ALDH1A1-dependent drug resistance in multiple myeloma. Oncotarget.
5:11986–11997. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Xia J, He Y, Meng B, Chen S, Zhang J, Wu
X, Zhu Y, Shen Y, Feng X, Guan Y, et al: NEK2 induces
autophagy-mediated bortezomib resistance by stabilizing Beclin-1 in
multiple myeloma. Mol Oncol. 14:763–778. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Xing Z, Zhang M and Wang X, Liu J, Liu G,
Feng K and Wang X: Silencing of Nek2 suppresses the proliferation,
migration and invasion and induces apoptosis of breast cancer cells
by regulating ERK/MAPK signaling. J Mol Histol. 52:809–821. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Szafarowski T, Sierdziński J, Ludwig N,
Głuszko A, Filipowska A and Szczepański MJ: Assessment of cancer
stem cell marker expression in primary head and neck squamous cell
carcinoma shows prognostic value for aldehyde dehydrogenase
(ALDH1A1). Eur J Pharmacol. 867:1728372020. View Article : Google Scholar : PubMed/NCBI
|
|
192
|
Gupta V, Maurya MK, Agarwal P, Kumar M,
Sagar M, Raghuvanshi S and Gupta S: Expression of aldehyde
dehydrogenase 1A1 in oral squamous cell carcinoma and its
correlation with clinicopathological parameters. Natl J Maxillofac
Surg. 13:208–215. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Namekawa T, Ikeda K, Horie-Inoue K, Suzuki
T, Okamoto K, Ichikawa T, Yano A, Kawakami S and Inoue S: ALDH1A1
in patient-derived bladder cancer spheroids activates retinoic acid
signaling leading to TUBB3 overexpression and tumor progression.
Int J Cancer. 146:1099–1113. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Li X, Xu Q, Fu X and Luo W: ALDH1A1
overexpression is associated with the progression and prognosis in
gastric cancer. BMC Cancer. 14:7052014. View Article : Google Scholar : PubMed/NCBI
|
|
195
|
van der Waals LM, Borel Rinkes IHM and
Kranenburg O: ALDH1A1 expression is associated with poor
differentiation, ‘right-sidedness’ and poor survival in human
colorectal cancer. PLoS One. 13:e02055362018. View Article : Google Scholar : PubMed/NCBI
|
|
196
|
Yang L, Ren Y, Yu X, Qian F, Bian BS, Xiao
HL, Wang WG, Xu SL, Yang J, Cui W, et al: ALDH1A1 defines invasive
cancer stem-like cells and predicts poor prognosis in patients with
esophageal squamous cell carcinoma. Mod Pathol. 27:775–783. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
197
|
Yehya A, Youssef J, Hachem S, Ismael J and
Abou-Kheir W: Tissue-specific cancer stem/progenitor cells:
Therapeutic implications. World J Stem Cells. 15:323–341. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
198
|
Sládek NE, Kollander R, Sreerama L and
Kiang DT: Cellular levels of aldehyde dehydrogenases (ALDH1A1 and
ALDH3A1) as predictors of therapeutic responses to
cyclophosphamide-based chemotherapy of breast cancer: A
retrospective study. Rational individualization of
oxazaphosphorine-based cancer chemotherapeutic regimens. Cancer
Chemother Pharmacol. 49:309–321. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
199
|
Khoury T, Ademuyiwa FO, Chandrasekhar R,
Jabbour M, Deleo A, Ferrone S, Wang Y and Wang X: Aldehyde
dehydrogenase 1A1 expression in breast cancer is associated with
stage, triple negativity, and outcome to neoadjuvant chemotherapy.
Mod Pathol. 25:388–397. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
200
|
Sun M, Zhao H, Xiao Q, Yu Z, Song Z, Yao
W, Tang H, Guan S, Jin F and Wei M: Combined expression of aldehyde
dehydrogenase 1A1 and β-catenin is associated with lymph node
metastasis and poor survival in breast cancer patients following
cyclophosphamide treatment. Oncol Rep. 34:3163–3173. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
201
|
Narendra G, Raju B, Verma H, Kumar M, Jain
SK, Tung GK, Thakur S, Kaur R, Kaur S, Sapra B and Silakari O:
Scaffold hopping based designing of selective ALDH1A1 inhibitors to
overcome cyclophosphamide resistance: Synthesis and biological
evaluation. RSC Med Chem. 15:309–321. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
202
|
Wang D and Wang H: Oxazaphosphorine
bioactivation and detoxification The role of xenobiotic receptors.
Acta Pharm Sin B. 2:10.1016/j.apsb.2012.02.004. 2012. View Article : Google Scholar
|
|
203
|
Paul SK, Guendouzi A, Banerjee A,
Guendouzi A and Haldar R: Identification of approved drugs with
ALDH1A1 inhibitory potential aimed at enhancing chemotherapy
sensitivity in cancer cells: An in-silico drug repurposing
approach. J Biomol Struct Dyn. 1–15. 2024.doi:
10.1080/07391102.2023.2300127 (Epub ahead of print). View Article : Google Scholar
|
|
204
|
Lu C, Li X, Ren Y and Zhang X: Disulfiram:
A novel repurposed drug for cancer therapy. Cancer Chemother
Pharmacol. 87:159–172. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
205
|
Yip NC, Fombon IS, Liu P, Brown S,
Kannappan V, Armesilla AL, Xu B, Cassidy J, Darling JL and Wang W:
Disulfiram modulated ROS-MAPK and NFκB pathways and targeted breast
cancer cells with cancer stem cell-like properties. Br J Cancer.
104:1564–1574. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
206
|
Kim JY, Cho Y, Oh E, Lee N, An H, Sung D,
Cho TM and Seo JH: Disulfiram targets cancer stem-like properties
and the HER2/Akt signaling pathway in HER2-positive breast cancer.
Cancer Lett. 379:39–48. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
207
|
Kim YJ, Kim JY, Lee N, Oh E, Sung D, Cho
TM and Seo JH: Disulfiram suppresses cancer stem-like properties
and STAT3 signaling in triple-negative breast cancer cells. Biochem
Biophys Res Commun. 486:1069–1076. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
208
|
Lin L, Hutzen B, Lee HF, Peng Z, Wang W,
Zhao C, Lin HJ, Sun D, Li PK, Li C, et al: Evaluation of STAT3
signaling in ALDH+ and ALDH+/CD44+/CD24-subpopulations of breast
cancer cells. PLoS One. 8:e828212013. View Article : Google Scholar : PubMed/NCBI
|
|
209
|
Nourbakhsh M, Farzaneh S, Taghikhani A,
Zarghi A and Noori S: The effect of a newly synthesized ferrocene
derivative against MCF-7 breast cancer cells and spheroid stem
cells through ROS production and inhibition of JAK2/STAT3 signaling
pathway. Anticancer Agents Med Chem. 20:875–886. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
210
|
Tsao AN, Chuang YS, Lin YC, Su Y and Chao
TC: Dinaciclib inhibits the stemness of two subtypes of human
breast cancer cells by targeting the FoxM1 and Hedgehog signaling
pathway. Oncol Rep. 47:1052022. View Article : Google Scholar : PubMed/NCBI
|
|
211
|
Teng CJ, Cheng PT, Cheng YC, Tsai JR, Chen
MC and Lin H: Dinaciclib inhibits the growth of acute myeloid
leukemia cells through either cell cycle-related or ERK1/STAT3/MYC
pathways. Toxicol In Vitro. 96:1057682024. View Article : Google Scholar : PubMed/NCBI
|
|
212
|
Liu C, Dong L, Sun Z, Wang L, Wang Q, Li
H, Zhang J and Wang X: Esculentoside A suppresses breast cancer
stem cell growth through stemness attenuation and apoptosis
induction by blocking IL-6/STAT3 signaling pathway. Phytother Res.
32:2299–2311. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
213
|
Simões BM, O'Brien CS, Eyre R, Silva A, Yu
L, Sarmiento-Castro A, Alférez DG, Spence K, Santiago-Gómez A,
Chemi F, et al: Anti-estrogen resistance in human breast tumors is
driven by JAG1-NOTCH4-dependent cancer stem cell activity. Cell
Rep. 12:1968–1977. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
214
|
Notas G, Pelekanou V, Kampa M, Alexakis K,
Sfakianakis S, Laliotis A, Askoxilakis J, Tsentelierou E, Tzardi M,
Tsapis A and Castanas E: Tamoxifen induces a pluripotency signature
in breast cancer cells and human tumors. Mol Oncol. 9:1744–1759.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
215
|
Li J, Zhang B, Yang YF, Jin J and Liu YH:
Aldehyde dehydrogenase 1 as a predictor of the neoadjuvant
chemotherapy response in breast cancer: A meta-analysis. Medicine
(Baltimore). 97:e120562018. View Article : Google Scholar : PubMed/NCBI
|
|
216
|
Alamgeer M, Ganju V, Kumar B, Fox J, Hart
S, White M, Harris M, Stuckey J, Prodanovic Z, Schneider-Kolsky ME
and Watkins DN: Changes in aldehyde dehydrogenase-1 expression
during neoadjuvant chemotherapy predict outcome in locally advanced
breast cancer. Breast Cancer Res. 16:R442014. View Article : Google Scholar : PubMed/NCBI
|
|
217
|
Lee A, Won KY, Lim SJ, Cho SY, Han SA,
Park S and Song JY: ALDH1 and tumor infiltrating lymphocytes as
predictors for neoadjuvant chemotherapy response in breast cancer.
Pathol Res Pract. 214:619–624. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
218
|
Allison SE, Chen Y, Petrovic N, Zhang J,
Bourget K, Mackenzie PI and Murray M: Activation of ALDH1A1 in
MDA-MB-468 breast cancer cells that over-express CYP2J2 protects
against paclitaxel-dependent cell death mediated by reactive oxygen
species. Biochem Pharmacol. 143:79–89. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
219
|
Kakarala M, Brenner DE, Korkaya H, Cheng
C, Tazi K, Ginestier C, Liu S, Dontu G and Wicha MS: Targeting
breast stem cells with the cancer preventive compounds curcumin and
piperine. Breast Cancer Res Treat. 122:777–785. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
220
|
Kesharwani RK, Srivastava V, Singh P,
Rizvi SI, Adeppa K and Misra K: A novel approach for overcoming
drug resistance in breast cancer chemotherapy by targeting new
synthetic curcumin analogues against aldehyde dehydrogenase 1
(ALDH1A1) and glycogen synthase kinase-3 β (GSK-3β). Appl Biochem
Biotechnol. 176:1996–2017. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
221
|
Li X, Wang X, Xie C, Zhu J, Meng Y, Chen
Y, Li Y, Jiang Y, Yang X, Wang S, et al: Sonic hedgehog and
Wnt/β-catenin pathways mediate curcumin inhibition of breast cancer
stem cells. Anticancer Drugs. 29:208–215. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
222
|
Attia YM, El-Kersh DM, Ammar RA, Adel A,
Khalil A, Walid H, Eskander K, Hamdy M, Reda N, Mohsen NE, et al:
Inhibition of aldehyde dehydrogenase-1 and p-glycoprotein-mediated
multidrug resistance by curcumin and vitamin D3 increases
sensitivity to paclitaxel in breast cancer. Chem Biol Interact.
315:1088652020. View Article : Google Scholar : PubMed/NCBI
|
|
223
|
Tanei T, Morimoto K, Shimazu K, Kim SJ,
Tanji Y, Taguchi T, Tamaki Y and Noguchi S: Association of breast
cancer stem cells identified by aldehyde dehydrogenase 1 expression
with resistance to sequential Paclitaxel and epirubicin-based
chemotherapy for breast cancers. Clin Cancer Res. 15:4234–4241.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
224
|
Wang R, Yang L, Li S, Ye D, Yang L, Liu Q,
Zhao Z, Cai Q, Tan J and Li X: Quercetin inhibits breast cancer
stem cells via downregulation of aldehyde dehydrogenase 1A1
(ALDH1A1), chemokine receptor type 4 (CXCR4), Mucin 1 (MUC1), and
epithelial cell adhesion molecule (EpCAM). Med Sci Monit.
24:412–420. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
225
|
Castro NP, Rangel MC, Merchant AS,
MacKinnon G, Cuttitta F, Salomon DS and Kim YS: Sulforaphane
suppresses the growth of triple-negative breast cancer stem-like
cells in vitro and in vivo. Cancer Prev Res (Phila). 12:147–158.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
226
|
Li Y, Zhang T, Korkaya H, Liu S, Lee HF,
Newman B, Yu Y, Clouthier SG, Schwartz SJ, Wicha MS and Sun D:
Sulforaphane, a dietary component of broccoli/broccoli sprouts,
inhibits breast cancer stem cells. Clin Cancer Res. 16:2580–2590.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
227
|
Leung HW, Ko CH, Yue GL, Herr I and Lau
CS: The natural agent 4-vinylphenol targets metastasis and stemness
features in breast cancer stem-like cells. Cancer Chemother
Pharmacol. 82:185–197. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
228
|
Wang W, He S, Zhang R, Peng J, Guo D,
Zhang J, Xiang B and Li L: ALDH1A1 maintains the cancer stem-like
cells properties of esophageal squamous cell carcinoma by
activating the AKT signal pathway and interacting with β-catenin.
Biomed Pharmacother. 125:1099402020. View Article : Google Scholar : PubMed/NCBI
|
|
229
|
Jiang Y, Song H, Jiang L, Qiao Y, Yang D,
Wang D and Li J: Silybin prevents prostate cancer by inhibited the
ALDH1A1 expression in the retinol metabolism pathway. Front Cell
Dev Biol. 8:5743942020. View Article : Google Scholar : PubMed/NCBI
|
|
230
|
Scambia G, De Vincenzo R, Ranelletti FO,
Panici PB, Ferrandina G, D'Agostino G, Fattorossi A, Bombardelli E
and Mancuso S: Antiproliferative effect of silybin on
gynaecological malignancies: Synergism with cisplatin and
doxorubicin. Eur J Cancer. 32A:877–882. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
231
|
Bhatia N, Zhao J, Wolf DM and Agarwal R:
Inhibition of human carcinoma cell growth and DNA synthesis by
silibinin, an active constituent of milk thistle: Comparison with
silymarin. Cancer Lett. 147:77–84. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
232
|
Bian Y, Shan G, Bi G, Liang J, Hu Z, Sui
Q, Shi H, Zheng Z, Yao G, Wang Q, et al: Targeting ALDH1A1 to
enhance the efficacy of KRAS-targeted therapy through ferroptosis.
Redox Biol. 77:1033612024. View Article : Google Scholar : PubMed/NCBI
|
|
233
|
Galiè M: RAS as supporting actor in breast
cancer. Front Oncol. 9:11992019. View Article : Google Scholar : PubMed/NCBI
|
|
234
|
Tao S, Wang S, Moghaddam SJ, Ooi A,
Chapman E, Wong PK and Zhang DD: Oncogenic KRAS confers
chemoresistance by upregulating NRF2. Cancer Res. 74:7430–7441.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
235
|
Kim D, Choi BH, Ryoo IG and Kwak MK: High
NRF2 level mediates cancer stem cell-like properties of aldehyde
dehydrogenase (ALDH)-high ovarian cancer cells: Inhibitory role of
all-trans retinoic acid in ALDH/NRF2 signaling. Cell Death Dis.
9:8962018. View Article : Google Scholar : PubMed/NCBI
|
|
236
|
Piao S, Ojha R, Rebecca VW, Samanta A, Ma
XH, Mcafee Q, Nicastri MC, Buckley M, Brown E, Winkler JD, et al:
ALDH1A1 and HLTF modulate the activity of lysosomal autophagy
inhibitors in cancer cells. Autophagy. 13:2056–2071. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
237
|
Varisli L, Cen O and Vlahopoulos S:
Dissecting pharmacological effects of chloroquine in cancer
treatment: Interference with inflammatory signaling pathways.
Immunology. 159:257–278. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
238
|
Vlahopoulos S, Critselis E, Voutsas IF,
Perez SA, Moschovi M, Baxevanis CN and Chrousos GP: New use for old
drugs? Prospective targets of chloroquines in cancer therapy. Curr
Drug Targets. 15:843–851. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
239
|
Liang DH, Choi DS, Ensor JE, Kaipparettu
BA, Bass BL and Chang JC: The autophagy inhibitor chloroquine
targets cancer stem cells in triple negative breast cancer by
inducing mitochondrial damage and impairing DNA break repair.
Cancer Lett. 376:249–258. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
240
|
Stagni V, Kaminari A, Sideratou Z,
Sakellis E, Vlahopoulos SA and Tsiourvas D: Targeting breast cancer
stem-like cells using chloroquine encapsulated by a
triphenylphosphonium-functionalized hyperbranched polymer. Int J
Pharm. 585:1194652020. View Article : Google Scholar : PubMed/NCBI
|
|
241
|
Panagiotaki KN, Sideratou Z, Vlahopoulos
SA, Paravatou-Petsotas M, Zachariadis M, Khoury N, Zoumpourlis V
and Tsiourvas D: A Triphenylphosphonium-functionalized
mitochondriotropic nanocarrier for efficient co-delivery of
doxorubicin and chloroquine and enhanced antineoplastic activity.
Pharmaceuticals (Basel). 10:912017. View Article : Google Scholar : PubMed/NCBI
|
|
242
|
Visus C, Wang Y, Lozano-Leon A, Ferris RL,
Silver S, Szczepanski MJ, Brand RE, Ferrone CR, Whiteside TL,
Ferrone S, et al: Targeting ALDH(bright) human carcinoma-initiating
cells with ALDH1A1-specific CD8+ T cells. Clin Cancer
Res. 17:6174–6184. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
243
|
Liu C, Qiang J, Deng Q, Xia J, Deng L,
Zhou L, Wang D, He X, Liu Y, Zhao B, et al: ALDH1A1 activity in
tumor-initiating cells remodels myeloid-derived suppressor cells to
promote breast cancer progression. Cancer Res. 81:5919–5934. 2021.
View Article : Google Scholar : PubMed/NCBI
|
